| |
By lung-function change category (based on relative change in FVC%)a
|
|---|
| |
Stable [A]
|
Marginal [B]
|
Significant [C]
|
Relative effect measure (95 % CI)
|
|---|
| |
(N = 250)
|
(N = 98)
|
(N = 142)
|
[C] vs. [A]
|
[C] vs. [B]
|
[B] vs. [A]
|
|---|
| |
12-Month IR per Patient
|
IRR
|
|
Rate of suspected AEx
|
0.26
|
0.47
|
0.74
|
2.87 (1.71–4.82)
|
1.58 (0.95–2.64)
|
1.82 (1.02–3.23)
|
| |
12-Month Risk
|
OR
|
|
Risk of suspected AEx
|
19.2 %
|
37.1 %
|
50.9 %
|
4.37 (2.09–9.16)
|
1.76 (0.81–3.80)
|
2.49 (1.28–4.82)
|
|
Risk of progression
|
62.6 %
|
76.2 %
|
85.6 %
|
3.56 (1.66–7.64)
|
1.86 (0.81–4.26)
|
1.92 (0.91–4.04)
|
|
Mortalityb
|
Risk by 12 Months
|
HR
|
|
Death due to any cause
|
6.4 %
|
13.1 %
|
28.0 %
|
5.05 (2.75–9.27)
|
1.85 (1.05–3.26)
|
2.73 (1.51–4.94)
|
|
Death due to IPF
|
5.5 %
|
10.3 %
|
24.3 %
|
6.23 (2.96–13.14)
|
1.94 (1.01–3.70)
|
3.22 (1.59–6.53)
|
|
Death due to AEx
|
5.0 %
|
9.3 %
|
13.1 %
|
3.91 (1.56–9.84)
|
1.22 (0.54–2.77)
|
3.21 (1.41–7.30)
|
-
AEx acute exacerbation, IR incidence rate, IRR incidence rate ratio, OR odds ratio, HR hazard ratio
-
aLung-function change categories were defined as the relative change in FVC% from index to approximately 6 months following IPF diagnosis. "Stable" was defined as decline <5 %. "Marginal" was defined as decline ≥5 % and <10 %, while "Significant" was defined as decline ≥10 %
-
bKaplan-Meier survival analysis was used to estimate the risk of death by 12 months
